Atossa Genetics

Atossa Genetics Inc. is a breast health company that focuses on breast cancer prevention. It is an 11-

employee company, which was launched in 2013 and is based in Seattle. Currently, the company is doing very

well: they have no debt and their stock price recently went up.

The scientific director started the company on the basis of data published by the Greek cancer researcher Papanikolaou

(the inventor of the Pap smear). The data showed that fluids from the breast of patients with cancer were different from

that of healthy women. The company invented a device to collect the fluids and test them for cancer. The device is a

reusable hand pump that aspires the fluids from the nipple without being invasive or painful. A few drops is all that is

needed to analyze the fluid cytologically. The device will be on the market shortly, after the company completes 501k FDA

clearance. They expect to obtain a revenue of $600 per patient. The company claims that this device will be particularly

useful for those women who have dense breast tissue and for whom a mammography may not be effective in the

detection of cancer. They say that with this device we can detect pre-cancer changes, something that cannot be done with

the current available tests, thus making the device an excellent tool for prognosis.

The company is currently developing a treatment for breast cancer which is based on the injection of drugs through the

nipple via micro-catheters. In addition, the company is developing four tests: Fore cyte test; Full cyte test; Next cyte test

and Argus cyte test. Fore cyte is a test to perform cytological analyses of the breast fluids. If the results are positive, then

there is the second test, Full cyte, which is used to locate the condition. This test also determines the exact location of the

cancerous cells. The third test is Next cyte, and used for women who have been diagnosed with breast cancer. It is a

genetic test that profiles 22 genes. The forth test, Argus cyte, is for women who survived breast cancer and want to avoid

recurrence through the monitoring of their breast health. Atossa Genetics is currently looking for partners to perform

clinical trials of their four tests.